Pro-Dex (NASDAQ:PDEX) Price Target Raised to $80.00

Pro-Dex logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Ascendiant Capital Markets raised Pro-Dex’s price target to $80 from $74 and maintained a Buy rating, implying 21.84% upside from the current share price.
  • Analyst views are mixed but lean positive: MarketBeat reports a Moderate Buy consensus and an $80 consensus target, with two Buy ratings and one Hold.
  • Pro-Dex’s latest quarterly results beat estimates, reporting $0.92 earnings per share versus $0.67 expected and revenue of $20.56 million versus $20.40 million expected.
  • Five stocks to consider instead of Pro-Dex.

Pro-Dex (NASDAQ:PDEX - Get Free Report) had its price objective upped by investment analysts at Ascendiant Capital Markets from $74.00 to $80.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a "buy" rating on the medical instruments supplier's stock. Ascendiant Capital Markets's price objective indicates a potential upside of 21.84% from the company's current price.

A number of other research firms also recently weighed in on PDEX. Weiss Ratings upgraded Pro-Dex from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, November 10th. Zacks Research downgraded shares of Pro-Dex from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 9th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $80.00.

Check Out Our Latest Stock Report on PDEX

Pro-Dex Stock Performance

Shares of Pro-Dex stock opened at $65.66 on Monday. Pro-Dex has a fifty-two week low of $28.81 and a fifty-two week high of $77.00. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.19 and a quick ratio of 2.49. The firm has a market capitalization of $210.11 million, a P/E ratio of 17.99 and a beta of 0.12. The company's 50 day moving average price is $65.04 and its two-hundred day moving average price is $57.67.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pro-Dex had a net margin of 15.12% and a return on equity of 26.18%. The firm had revenue of $20.56 million for the quarter, compared to analysts' expectations of $20.40 million. On average, equities analysts forecast that Pro-Dex will post 3.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pro-Dex news, CFO Alisha Charlton sold 2,300 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the completion of the sale, the chief financial officer owned 21,870 shares in the company, valued at approximately $1,340,631. The trade was a 9.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of the company's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $60.58, for a total transaction of $1,165,256.30. Following the transaction, the chief executive officer owned 79,993 shares in the company, valued at approximately $4,845,975.94. The trade was a 19.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 22,300 shares of company stock worth $1,351,657. 48.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Ellsworth Advisors LLC acquired a new stake in shares of Pro-Dex in the 3rd quarter worth about $1,166,000. Bank of New York Mellon Corp bought a new position in Pro-Dex in the 2nd quarter valued at about $678,000. Corsair Capital Management L.P. bought a new position in Pro-Dex in the 1st quarter valued at about $532,000. First Trust Advisors LP boosted its stake in Pro-Dex by 26.2% during the 3rd quarter. First Trust Advisors LP now owns 7,487 shares of the medical instruments supplier's stock valued at $517,000 after purchasing an additional 1,553 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its stake in Pro-Dex by 7,790.1% during the 3rd quarter. Global Retirement Partners LLC now owns 78,901 shares of the medical instruments supplier's stock valued at $5,444,000 after purchasing an additional 77,901 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors and hedge funds.

About Pro-Dex

(Get Free Report)

Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pro-Dex Right Now?

Before you consider Pro-Dex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.

While Pro-Dex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines